Trial completion • Combination therapy • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)